Regenxbio
RGNXREGENXBIO is a clinical-stage biotechnology company focused on developing and commercializing gene therapies using its proprietary NAV Technology Platform.
Earnings
Next report
Nov 5, 2026 (in 2 months)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
Profile
REGENXBIO is a clinical-stage biotechnology company focused on developing and commercializing gene therapies using its proprietary NAV Technology Platform. The company utilizes adeno-associated virus (AAV) vectors to deliver functional genes that address genetic defects, aiming to provide one-time curative treatments for chronic and life-threatening diseases. Its internal pipeline primarily targets retinal, neuromuscular, and neurodegenerative disorders.
A leading clinical-stage gene therapy firm with a proprietary AAV vector platform that underpins both its internal pipeline and several FDA-approved therapies marketed by licensees.
FAQ
- What is Regenxbio's market cap?
- Regenxbio (RGNX) has a market capitalization of $524.5M and trades on NASDAQ.
- What is Regenxbio's revenue and profitability?
- Regenxbio generated $174.5M in trailing twelve-month revenue with a net loss of $196.4M, representing a net margin of -112.6%. Gross margin stands at 59.7%, with free cash flow of -$249.7M. The latest reported period is Q2 2026.
- Who are Regenxbio's competitors?
- Regenxbio's key competitors include Ultragenyx Pharmaceutical, Sarepta Therapeutics, Regeneron Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Regenxbio partner with?
- Regenxbio's notable partners include AbbVie, Nippon Shinyaku, Novartis, and others.
- Where is Regenxbio headquartered?
- Regenxbio is headquartered in United States of America and employs approximately 344 people. It has been publicly traded since 2015.
